MTOR and depressive disorder: Among them, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation, BDNF and mammalian/mechanistic target of rapamycin (mTOR)-mediated signaling, synaptic protein expression and synaptogenesis are framed with a focus on neuroplasticity to explain the potent and sustained depression treatment effects of these compounds [113].